Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K, Hatakeyama S, Numakura K, Tanaka T, Oikawa M, Noro D, Hosogoe S, Narita S, Inoue T, Yoneyama T, Ito H, Nishimura S, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Kido K, et al. Among authors: kawaguchi t. Int J Clin Oncol. 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16. Int J Clin Oncol. 2021. PMID: 33067647
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H, Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Iwabuchi I, Ogasawara M, Kawaguchi T. Murasawa H, et al. Among authors: kawaguchi t. Int J Clin Oncol. 2017 Feb;22(1):159-165. doi: 10.1007/s10147-016-1029-2. Epub 2016 Aug 17. Int J Clin Oncol. 2017. PMID: 27534866
Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.
Okita K, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Fujita N, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Masumori N, Kitamura H, Ohyama C. Okita K, et al. Among authors: kawaguchi t. Clin Genitourin Cancer. 2019 Jun;17(3):e440-e446. doi: 10.1016/j.clgc.2019.01.006. Epub 2019 Jan 17. Clin Genitourin Cancer. 2019. PMID: 30772204
C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Hamano I, Fujita N, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Masumori N, Kitamura H, Ohyama C. Konishi S, et al. Among authors: kawaguchi t. Int J Urol. 2019 Oct;26(10):992-998. doi: 10.1111/iju.14078. Epub 2019 Jul 24. Int J Urol. 2019. PMID: 31342557
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
Konishi S, Hatakeyama S, Numakura K, Narita S, Inoue T, Saito M, Tokui N, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Narita S, Kawaguchi T, Habuchi T, Ohyama C. Konishi S, et al. Among authors: kawaguchi t. Clin Genitourin Cancer. 2019 Oct;17(5):e1080-e1089. doi: 10.1016/j.clgc.2019.07.006. Epub 2019 Jul 20. Clin Genitourin Cancer. 2019. PMID: 31416753
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Okita K, et al. Among authors: kawaguchi t. Clin Genitourin Cancer. 2020 Apr;18(2):e103-e111. doi: 10.1016/j.clgc.2019.09.006. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31810867
Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Koizumi A, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nomura K, Habuchi T. Narita S, et al. Among authors: kawaguchi t. Int J Clin Oncol. 2020 May;25(5):912-920. doi: 10.1007/s10147-019-01614-8. Epub 2020 Jan 9. Int J Clin Oncol. 2020. PMID: 31919691
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Numakura K, Kido K, Noro D, Oikawa M, Hosogoe S, Tokui N, Yamamoto H, Narita S, Ito H, Yoneyama T, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Tanaka T, et al. Among authors: kawaguchi t. Int J Urol. 2020 Dec;27(12):1095-1100. doi: 10.1111/iju.14363. Epub 2020 Sep 6. Int J Urol. 2020. PMID: 32893401
2,569 results